Elizabeth B. Sobolik

This paper describes the discovery of a potent monoclonal antibody, 4F11, that neutralizes HMPV with high efficacy and low resistance potential.

This study identifies mutations in VEEV nsP4 that reduce susceptibility to 4-FlU, shows these mutations do not fully prevent 4-FlU's therapeutic effect in mice, and highlights its potential as an antiviral for alphavirus encephalitis.

This paper develops an attenuated SARS-CoV-2 virus expressing nanoluciferase to identify and validate drug-resistant mutants to nirmatrelvir without using wild-type virus.

This study evaluates late-onset antiviral treatment in immunocompromised mice with persistent SARS-CoV-2 infection, finding that 4-FlU significantly reduces virus load, while paxlovid causes viral rebound.